Health Care

Discover why C4 Therapeutics’ chief medical officer is buying shares at zero cost after RSU vesting—insider confidence signals a biotech upside worth watching.

Indivior insider sale by CSO Christian Heidbreder shows routine 10‑b‑5 trading amid a 161% YTD rally, confirming confidence in future clinical gains.

MoonLake CEO’s planned July 9th sale of 33,936 shares at $20.01 signals disciplined portfolio management, not panic, amid rising clinical prospects.

Bruls Annette’s modest 109‑share sale at Edwards Lifesciences signals routine liquidity needs, not a warning—insider buying stays strong and the company’s growth outlook remains solid.

Insight into TWST insider activity: CFO sells 2,399 shares at $94.33—routine, routine‑level liquidity moves, not a warning for investors.

Oncology Institute insider buying spikes: director Chernett Jorey’s latest 15,000‑share purchase signals confidence in value‑based care growth and a potential undervalued upside for long‑term investors.

RIGEL Pharma insider buys 24,400 shares, boosting confidence as stock climbs near 52‑week highs and social buzz spikes—investors note strong momentum.

Insider option grants at Cellectar Biosciences signal executive confidence and a bullish outlook for the drug‑development biotech, despite a volatile stock.

Aziz Kabeer’s July 10 insider purchase signals confidence in Elevance Health’s growth—boosting investor sentiment amid expanding Medicare & community‑health initiatives.

Cue Biopharma’s insider buys and new RSU grants signal executive confidence, pairing a $50 M private placement with strong pipeline prospects for investors.